Parsaclisib clinical trials
Also written INCB050465 and IBI376.
How each study uses parsaclisib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the parsaclisib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 6
Incyte Corporation (24) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Mayo Clinic (1) · Walter Hanel (1) · Incyte Biosciences Japan GK (1) · Fudan University (1) · Chinese PLA General Hospital (1) · Henan Cancer Hospital (1)
Often tested with
Tested in the same studies.
Itacitinib (2) · Rituximab (2) · Epacadostat (2) · Cyclophosphamide (1) · Doxorubicin (1) · Prednisone (1) · Vincristine (1) · Romidepsin (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test parsaclisib.
Studies
Open first, then newest update. How each study uses parsaclisib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 33
- IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.RecruitingPhase 2Chinese PLA General HospitalNCT05073250Written as IBI376How we know
- Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCLNot yet recruitingPhase 1/2Fudan UniversityNCT05238064Written as ParsaclisibHow we know
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingPhase 2Incyte CorporationNCT04509700Written as ParsaclisibHow we know
- A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)TerminatedPhase 1/2Incyte CorporationNCT04809467Written as parsaclisibHow we know
- Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaActive, not recruitingPhase 1Mayo ClinicNCT04323956Written as ParsaclisibHow we know
- PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell LymphomaTerminatedPhase 1Henan Cancer HospitalNCT05083208Written as ParsaclisibHow we know
- Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaTerminatedPhase 3Incyte CorporationNCT05073458Written as parsaclisinibHow we know
- To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)TerminatedPhase 3Incyte CorporationNCT04551066Written as parsaclisibHow we know
- To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)TerminatedPhase 3Incyte CorporationNCT04551053Written as parsaclisibHow we know
- A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)CompletedPhase 2Incyte CorporationNCT02998476Written as ParsaclisibHow we know
- Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)CompletedPhase 1Incyte CorporationNCT03039114Written as ParsaclisibHow we know
- A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)CompletedPhase 2Incyte CorporationNCT03144674Written as ParsaclisibHow we know
- A Study of INCB050465 in Participants With Autoimmune Hemolytic AnemiaCompletedPhase 2Incyte CorporationNCT03538041Written as ParsaclisibHow we know
- A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorCompletedPhase 2Incyte CorporationNCT03235544Written as ParsaclisibHow we know
- A Study of INCB050465 in Relapsed or Refractory Follicular LymphomaCompletedPhase 2Incyte CorporationNCT03126019Written as ParsaclisibHow we know
- Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasCompletedPhase 1Walter HanelNCT04774068Written as ParsaclisibHow we know
- Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)CompletedPhase 2Incyte Biosciences Japan GKNCT04434937Written as parsaclisibHow we know
- IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone LymphomaCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT04298879Written as IBI376How we know
- A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedPhase 2Incyte CorporationNCT02718300Written as ParsaclisibHow we know
- Parsaclisib in Patients With Relapsed or Refractory Follicular LymphomaWithdrawnPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05867030Written as parsaclisibHow we know
See all 33 studies that test parsaclisib →
Given beside what is tested · 3 — parsaclisib is usual care or a partner of the new treatment
- To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingPhase 1/2Incyte Biosciences Japan GKNCT04661007Written as parsaclisibHow we know
- INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedPhase 1Incyte CorporationNCT03424122Written as ParsaclisibHow we know
- An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesTerminatedPhase 1/2Incyte CorporationNCT02265510Written as INCB050465How we know
Codes
What other systems call parsaclisib · ClinicalTrials.gg INT001234
- MeSH (NLM) C000656179parsaclisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) OS7097575KPARSACLISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q76802661parsaclisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113434ParsaclisibOne source FDA
- DrugBank DB14867One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656179 | parsaclisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | OS7097575K | PARSACLISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q76802661 | parsaclisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113434 | Parsaclisib | One source FDA |
| DrugBank | DB14867 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.